ITeos Therapeutics Inc Ordinary Shares ITOS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $9.69
- Day Range
- $9.59–10.08
- 52-Week Range
- $8.20–18.75
- Bid/Ask
- $9.80 / $10.09
- Market Cap
- $365.95 Mil
- Volume/Avg
- 445,192 / 521,262
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.53
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 157
Comparables
Valuation
|
Metric
|
ITOS
|
ARTV
|
CGON
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.55 | — | 4.42 |
Price/Sales | 10.53 | 4.39 | 244.06 |
Price/Cash Flow | — | — | — |
Price/Earnings
ITOS
ARTV
CGON
Financial Strength
|
Metric
|
ITOS
|
ARTV
|
CGON
|
|---|---|---|---|
Quick Ratio | 17.70 | 4.43 | 46.66 |
Current Ratio | 18.08 | 4.59 | 47.57 |
Interest Coverage | — | — | — |
Quick Ratio
ITOS
ARTV
CGON
Profitability
|
Metric
|
ITOS
|
ARTV
|
CGON
|
|---|---|---|---|
Return on Assets (Normalized) | −12.36% | −16.21% | −15.24% |
Return on Equity (Normalized) | −14.12% | — | −26.61% |
Return on Invested Capital (Normalized) | −18.04% | — | −25.60% |
Return on Assets
ITOS
ARTV
CGON
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Kxjbrfwp | Yyhj | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Gxzvncxwt | Qcgcch | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ykcqxblyp | Gwrlg | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Wwnbyfmc | Qyjwvjb | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Qtsspvmk | Kym | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Lgsclywh | Khjl | $29.2 Bil | |||
| Moderna Inc
MRNA
| Lgwhqwfp | Mgr | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Dmxfjcfv | Gzs | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Znpfflr | Nydtlz | $13.2 Bil | |||
| Incyte Corp
INCY
| Gqydyxz | Vrwkxxz | $13.0 Bil |
United States